Daewoong Pharmaceutical to export Nabota to New Zealand, Israel, Ukraine
IndustryDec 20, 2018
South Korean drugmaker Daewoong Pharmaceutical Co. said Thursday it has signed deals to sell its type A botulinum toxin drug in New Zealand, Israel and Ukraine.The product, called Nabota, will be available in the three countries as early as 2020 in accordance with the three separate contracts, whose combined value amounts to $12 million, the company said.This photo, provided by South Korean drugmaker Daewoong Pharmaceutical Co., on Dec. 20, 2018, shows its BTX product, Nabota. (Yonhap)Douglas Ph